Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma

被引：1

作者：

Sidana, Surbhi ^{[1
]}

Bankova, Andriyana K. ^{[1
,2
]}

Hosoya, Hitomi ^{[1
]}

Kumar, Shaji K. ^{[3
]}

Holmes, Tyson H. ^{[4
]}

Tamaresis, John ^{[5
]}

Le, Anne ^{[1
,6
]}

Muffly, Lori S. ^{[1
]}

Maysel-Auslender, Sofia ^{[4
]}

Johnston, Laura ^{[1
]}

Arai, Sally ^{[1
]}

Lowsky, Robert ^{[1
]}

Meyer, Everett ^{[1
]}

Rezvani, Andrew ^{[1
]}

Weng, Wen-Kai ^{[1
]}

Frank, Matthew J. ^{[1
]}

Shiraz, Parveen ^{[1
]}

Maecker, Holden T. ^{[4
]}

Lu, Ying ^{[5
]}

Miklos, David B. ^{[1
]}

Shizuru, Judith A. ^{[1
]}

机构：

[1] Stanford Univ, Sch Med, Dept Med, Div BMT & Cell Therapy, Stanford, CA 94305 USA

[2] Natl Specialized Hosp Hematol Dis, Sofia, Bulgaria

[3] Mayo Clin, Div Hematol, Rochester, MN USA

[4] Stanford Univ, Sch Med, Inst Immun Transplantat & Infect, Stanford, CA USA

[5] Stanford Univ, Sch Med, Dept Biostat, Stanford, CA USA

[6] Jasper Therapeut, Stanford, CA USA

来源：

BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期

关键词：

PLUS G-CSF; BLOOD; TRANSPLANTATION; SURVIVAL; LENALIDOMIDE; CYCLOPHOSPHAMIDE; ENGRAFTMENT; COLLECTION; GUIDELINES; TRIAL;

D O I：

10.1038/s41408-024-01152-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MGTA-145 or GRO beta T, a CXCR2 agonist, has shown promising activity for hematopoietic stem cell (HSC) mobilization with plerixafor in pre-clinical studies and healthy volunteers. Twenty-five patients with multiple myeloma enrolled in a phase 2 trial evaluating MGTA-145 and plerixafor for HSC mobilization (NCT04552743). Plerixafor was given subcutaneously followed 2 h later by MGTA-145 (0.03 mg/kg) intravenously with same day apheresis. Mobilization/apheresis could be repeated for a second day in patients who collected <6 x10(6) CD34+ cells/kg. Lenalidomide and anti-CD38 antibody were part of induction therapy in 92% (n = 23) and 24% (n = 6) of patients, respectively. Median total HSC cell yield (CD34+ cells/kg x 10(6)) was 5.0 (range: 1.1-16.2) and day 1 yield was 3.4 (range: 0.3-16.2). 88% (n = 22) of patients met the primary endpoint of collecting 2 x10(6) CD34+ cells/kg in <= two days, 68% (n = 17) in one day. Secondary endpoints of collecting 4 and 6 x 10(6) CD34+ cells/kg in <= two days were met in 68% (n = 17) and 40% (n = 10) patients. Grade 1 or 2 adverse events (AE) were seen in 60% of patients, the most common AE being grade 1 pain, usually self-limited. All 19 patients who underwent transplant with MGTA-145 and plerixafor mobilized HSCs engrafted successfully, with durable engraftment at day 100. 74% (17 of 23) of grafts with this regimen were minimal residual disease negative by next generation flow cytometry. Graft composition for HSCs and immune cells were similar to a contemporaneous cohort mobilized with G-CSF and plerixafor.

引用

页数：10

共 42 条

[1] Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study [J].

Afifi, S. ;

Adel, N. G. ;

Devlin, S. ;

Duck, E. ;

Vanak, J. ;

Landau, H. ;

Chung, D. J. ;

Lendvai, N. ;

Lesokhin, A. ;

Korde, N. ;

Reich, L. ;

Landgren, O. ;

Giralt, S. ;

Hassoun, H. .

BONE MARROW TRANSPLANTATION, 2016, 51 (04) :546-552

[2]

Anaka M, 2021, TRANSPL CELL THER, V27, pS374, DOI [10.1016/s2666-6367(21)00483-8, 10.1016/S2666-6367(21)00483-8, DOI 10.1016/S2666-6367(21)00483-8]

[3] G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis [J].

Antar, A. ;

Otrock, Z. K. ;

Kharfan-Dabaja, M. A. ;

Ghaddara, H. A. ;

Kreidieh, N. ;

Mahfouz, R. ;

Bazarbachi, A. .

BONE MARROW TRANSPLANTATION, 2015, 50 (06) :813-817

[4] Using Confirmatory Factor Analysis to Evaluate Construct Validity of the Brief Pain Inventory (BPI) [J].

Atkinson, Thomas M. ;

Rosenfeld, Barry D. ;

Sit, Laura ;

Mendoza, Tito R. ;

Fruscione, Mike ;

Lavene, Dawn ;

Shaw, Mary ;

Li, Yuelin ;

Hay, Jennifer ;

Cleeland, Charles S. ;

Scher, Howard I. ;

Breitbart, William S. ;

Basch, Ethan .

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2011, 41 (03) :558-565

[5] The Brief Pain Inventory and Its "Pain At Its Worst in the Last 24 Hours" Item: Clinical Trial Endpoint Considerations [J].

Atkinson, Thomas M. ;

Mendoza, Tito R. ;

Sit, Laura ;

Passik, Steven ;

Scher, Howard I. ;

Cleeland, Charles ;

Basch, Ethan .

PAIN MEDICINE, 2010, 11 (03) :337-346

[6] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Hulin, Cyrille ;

Leleu, Xavier ;

Caillot, Denis ;

Escoffre, Martine ;

Arnulf, Bertrand ;

Macro, Margaret ;

Belhadj, Karim ;

Garderet, Laurent ;

Roussel, Murielle ;

Payen, Catherine ;

Mathiot, Claire ;

Fermand, Jean P. ;

Meuleman, Nathalie ;

Rollet, Sandrine ;

Maglio, Michelle E. ;

Zeytoonjian, Andrea A. ;

Weller, Edie A. ;

Munshi, Nikhil ;

Anderson, Kenneth C. ;

Richardson, Paul G. ;

Facon, Thierry ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc ;

Moreau, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) :1311-1320

[7] Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma [J].

Bal, Susan ;

Landau, Heather J. ;

Shah, Gunjan L. ;

Scordo, Michael ;

Dahi, Parastoo ;

Lahoud, Oscar B. ;

Hassoun, Hani ;

Hultcrantz, Malin ;

Korde, Neha ;

Lendvai, Nikoletta ;

Lesokhin, Alexander M. ;

Mailankody, Sham ;

Shah, Urvi A. ;

Smith, Eric ;

Devlin, Sean M. ;

Avecilla, Scott ;

Dogan, Ahmet ;

Roshal, Mikhail ;

Landgren, Ola ;

Giralt, Sergio A. ;

Chung, David J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (08) :1394-1401

[8] FACTORS THAT INFLUENCE COLLECTION AND ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELLS [J].

BENSINGER, W ;

APPELBAUM, F ;

ROWLEY, S ;

STORB, R ;

SANDERS, J ;

LILLEBY, K ;

GOOLEY, T ;

DEMIRER, T ;

SCHIFFMAN, K ;

WEAVER, C ;

CLIFT, R ;

CHAUNCEY, T ;

KLARNET, J ;

MONTGOMERY, P ;

PETERSDORF, S ;

WEIDEN, P ;

WITHERSPOON, R ;

BUCKNER, CD .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2547-2555

[9] Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials [J].

Chhabra, Saurabh ;

Callander, Natalie ;

Watts, Nicole L. ;

Costa, Luciano J. ;

Thapa, Bicky ;

Kaufman, Jonathan L. ;

Laubach, Jacob ;

Sborov, Douglas W. ;

Reeves, Brandi ;

Rodriguez, Cesar ;

Chari, Ajai ;

Silbermann, Rebecca ;

Anderson, Larry D., Jr. ;

Bal, Susan ;

Dhakal, Binod ;

Nathwani, Nitya ;

Shah, Nina ;

Medvedova, Eva ;

Bumma, Naresh ;

Holstein, Sarah A. ;

Costello, Caitlin ;

Jakubowiak, Andrzej ;

Wildes, Tanya M. ;

Schmidt, Timothy ;

Orlowski, Robert Z. ;

Shain, Kenneth H. ;

Cowan, Andrew J. ;

Dholaria, Bhagirathbhai ;

Cornell, R. Frank ;

Jerkins, James H. ;

Pei, Huiling ;

Cortoos, Annelore ;

Patel, Sharmila ;

Lin, Thomas S. ;

Usmani, Saad Z. ;

Richardson, Paul G. ;

Voorhees, Peter M. .

TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (03) :174e1-174e10

[10] Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor [J].

Condomines, Maud ;

Quittet, Philippe ;

Lu, Zhao-Yang ;

Nadal, Laure ;

Latry, Pascal ;

Lopez, Ernesto ;

Baudard, Marion ;

Requirand, Guilhem ;

Duperray, Christophe ;

Schved, Jean-Francois ;

Rossi, Jean-Francois ;

Tarte, Karin ;

Klein, Bernard .

JOURNAL OF IMMUNOLOGY, 2006, 176 (11) :6631-6639

← 1 2 3 4 5 →